Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer

Open Access

Peer-reviewed

Research Article

Adriana Camargo Carvalho,

Affiliation Centre for Evidence in Oncology, Department of Internal Medicine, University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil
⨯
Frederico Leal,

Affiliation Centre for Evidence in Oncology, Department of Internal Medicine, University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil
⨯
Andre Deeke Sasse

* E-mail: sasse@cevon.com.br

Affiliation Centre for Evidence in Oncology, Department of Internal Medicine, University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil

http://orcid.org/0000-0002-3038-3933

⨯

Reader Comments (0)

Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Cost-effectiveness analysis
Is the Subject Area "Cost-effectiveness analysis" applicable to this article?

Thanks for your feedback.
Brazil
Is the Subject Area "Brazil" applicable to this article?

Thanks for your feedback.
Colorectal cancer
Is the Subject Area "Colorectal cancer" applicable to this article?

Thanks for your feedback.
Monoclonal antibodies
Is the Subject Area "Monoclonal antibodies" applicable to this article?

Thanks for your feedback.
Metastasis
Is the Subject Area "Metastasis" applicable to this article?

Thanks for your feedback.
Adverse events
Is the Subject Area "Adverse events" applicable to this article?

Thanks for your feedback.
Palliative care
Is the Subject Area "Palliative care" applicable to this article?

Thanks for your feedback.